Bastion Trading Ltd has made a significant update regarding its investment in SkyAI, Inc. by filing a Schedule 13D/A with the SEC on October 29, 2026. This filing is crucial as it outlines changes to the terms of a tender offer agreement between the two companies, indicating a strategic shift in Bastion's approach to its holdings in SkyAI.
SkyAI, Inc., which operates in the finance services sector, is based in Melville, New York. The company has undergone a name change from Sharps Technology Inc. in April 2018. Bastion Trading's recent filing reveals its ongoing commitment to SkyAI, with details on the number of shares and warrants it holds.
According to the filing, Bastion Trading beneficially owns 2,188,169 shares of SkyAI, representing approximately 4.3% of the company's outstanding shares. The filing also indicates that Bastion Trading has entered into a tender offer support and settlement agreement with SkyAI, which includes several key amendments to the terms of the offer.
Specifically, the agreement allows for an increase in the maximum number of cash pre-funded warrants and cryptocurrency pre-funded warrants that can be tendered in the offer. Additionally, it includes provisions for cash stapled warrants and cryptocurrency stapled warrants, all of which can now be tendered at a price of $0.17 per warrant. The tender offer has also been extended until at least November 12, 2026.
Furthermore, the agreement stipulates that the reporting persons, including Bastion Trading, have agreed to tender all securities beneficially owned by them as part of the offer. This move may have implications for other stakeholders in SkyAI and could influence the broader market within the finance services sector, particularly as it relates to cryptocurrency.
The filing also details the ownership stakes of other entities associated with Bastion Trading. Lucio Holding, for instance, holds 2,940,075 shares, or about 5.8% of SkyAI, while Wei Zhu, a director associated with Bastion, may be deemed to beneficially own nearly 10% of the company when considering combined holdings.
As the situation develops, it remains to be seen how these changes will impact SkyAI's operations and its standing in the finance services industry. The filing does not specify what actions may follow this update, leaving stakeholders to anticipate future developments.
Read Next
Westlake BioPartners Discloses Major Stake in Latigo Biotherapeutics
Westlake BioPartners Acquires Significant Stake in Electra Therapeutics
Coletti Reports New Stock Transactions for Cintas Corp
Bain Capital Life Sciences acquires 9.99% stake in ADC Therapeutics
Studio City International Holdings reports major share transactions
Saba Capital Management acquires shares in New Germany Fund






